Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma

Tools

Item Type:	Article
Title:	Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma
Creators Name:	Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H.E., Rycak, L., Jamin, Y., Thway, K., Robinson, S.P., Roels, F., Witt, O., Fischer, M., Chesler, L. and Eilers, M.
Abstract:	Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma. No small molecules that target N-Myc, the protein encoded by MYCN, are clinically available. N-Myc forms a complex with the Aurora-A kinase, which protects N-Myc from proteasomal degradation. Although stabilization of N-Myc does not require the catalytic activity of Aurora-A, we show here that two Aurora-A inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degradation of N-Myc mediated by the Fbxw7 ubiquitin ligase. Disruption of the Aurora-A/N-Myc complex inhibits N-Myc-dependent transcription, correlating with tumor regression and prolonged survival in a mouse model of MYCN-driven neuroblastoma. We conclude that Aurora-A is an accessible target that makes destabilization of N-Myc a viable therapeutic strategy.
Keywords:	Antineoplastic Agents, Aurora Kinase A, Aurora Kinases, Azepines, Benzazepines, Cell Cycle Proteins, Cyclohexanecarboxylic Acids, F-Box Proteins, F-Box-WD Repeat-Containing Protein 7, Neuroblastoma, Proteasome Endopeptidase Complex, Protein-Serine-Threonine Kinases, Proto-Oncogene Proteins c-myc, Pyrimidines, Thiazoles, Tumor Cell Line, Ubiquitin-Protein Ligases, Animals, Mice
Source:	Cancer Cell
ISSN:	1535-6108
Publisher:	Cell Press / Elsevier
Volume:	24
Number:	1
Page Range:	75-89
Date:	8 July 2013
Additional Information:	Erratum in: Cancer Cell 30(2):357.
Official Publication:	https://doi.org/10.1016/j.ccr.2013.05.005
PubMed:	View item in PubMed

Repository Staff Only: item control page